Glenmark Pharmaceuticals today said its US-based subsidiary has received the nod of US health regulator Food and Drug Administration for marketing Ropinirole Hydrochloride tablets, used in the treatment of Parkinson's disease.
The company has got the approval for Ropinirole Hydrochloride tablets in 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, 4 mg and 5 mg strengths and will immediately commence marketing and distribution of the product in the US market, Glenmark said in a filing to the Bombay Stock Exchange.
Ropinirole Hydrochloride tablets are the generic version of GlaxoSmithKline's Requip tablets in the US market, it added.
Total sales for Ropinirole Hydrochloride tablets in the twelve-months period ending December 2009, were around 104 million dollars, Glenmark said quoting market research firm IMS Health.
